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 Implication for health policy/practice/research/medical education:
The burden of Hepatitis B virus infection is tremendous in resource-poor countries. Management of the chronic phase of the in-
fection is associated with numerous challenges. An accurate knowledge of these challenges will greatly assist policy makers and 
researchers in the ﬁght to eliminate this dreaded killer.
  c 2011 Kowsar M.P.Co. All rights reserved.
Chronic infection with hepatitis B virus (HBV) is a global public health problem because 
of its worldwide distribution and its potential to cause sequelae. HBV is most prevalent 
in China, South East Asia, sub-Saharan Africa, and the Amazon basin of South America 
where health care resources are most limited. Numerous challenges exist for eﬀective 
management of chronic HBV infection, particularly in resource-limited regions. These 
challenges include lack of accurate prevalence data, absence of a surveillance program, 
and poor political will of governments in resource-poor countries to enforce eﬀective 
measures to control the disease. There is a lack of understanding regarding HBV infec-
tion by both the general public and health care providers. A better understanding of the 
pathogenesis and treatment of this condition is necessary. The acute shortage of trained 
medical manpower necessary for accurate diagnosis and treatment of chronic hepati-
tis B (CHB) in resource-poor countries is a formidable challenge. The condition is com-
plicated by the continuing eﬄux of medical graduates from low-income economies to 
richer countries.
The most critical problem in the management of CHB is the high cost of laboratory 
tests and drugs. Drugs are also not readily available. Other challenges in the manage-
ment of CHB include stigmatization of patients, co-infection with other viruses, lack of 
management guidelines, and absence of an eﬀective patient referral system. To address 
these challenges, governments of resource-poor nations must be committed to budg-
etary allocation for the implementation of health programs. It is necessary to provide 
awareness campaigns, health education, proper screening of blood and blood products 
for transfusion, active screening, intensiﬁcation of existing childhood immunization, 
technical and ﬁnancial assistance from wealthier nations, and implementation of the 
recommendations outlined in the Global Hepatitis Policy (2010). 
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1. Introduction and Epidemiology
The hepatitis B virus (HBV) has infected approximately 
2 billion people worldwide, which represents one-third 
of the world population. Of these cases, 350 million (5–
7% of the world population) are chronically infected (1). 
Life-threatening liver disease (cirrhosis, liver failure, and 
hepatocellular carcinoma [HCC]) occurs in as many as 
40% of patients with hepatitis B. This infection is the 10th 
leading cause of death worldwide, resulting in 1.2 mil-
lion deaths per year. HCC is now the 5th most prevalent 
cancer worldwide, causing up to 500,000 deaths each 787
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year (1). Northern Europe, North America, and Australia 
have low HBV endemicity (population prevalence, < 2%); 
sub-Saharan Africa and the Far East have high endemic-
ity (population prevalence, > 8%); Eastern and Southern 
Europe, South America, and the remaining regions in Af-
rica and Asia have intermediate endemicity (population 
prevalence, 2–8%) (2). The continent of Africa encompass-
es a wide geographic area with a very large population 
and low-income economies. At least 65 million individu-
als with chronic HBV (CHB) infection live in Africa (3, 4). 
In high endemic areas of Africa and Asia, most HBV infec-
tions occur in the ﬁrst 5 years of life. Perinatal transmis-
sion predominates in East and South-East Asia; in Africa, 
most HBV transmissions occur before the age of 5 years 
through close contact within households, medical pro-
cedures, traditional scariﬁcation, and other unidentiﬁed 
mechanisms (5, 6). The vertical transmission rate may 
be lower in Africa than in Asia, partly because of a lower 
prevalence of hepatitis B e antigen (HBeAg) in African 
individuals, a major determinant of perinatal transmis-
sion (7, 8).
Nigeria is a sub-Saharan African country with a popu-
lation of approximately 150.7 million. The population 
grows by 2.3% annually, the gross domestic product 
(GDP) is 173.0 billion US dollars, the GDP per capita is 
1,118 US dollars, GDP growth is 5.6%, life expectancy is 47.9 
years, infant mortality is 85.8 per 1000 live births, and 
the literacy rate of women aged 15–24 years is 64.6% (9). 
It is the largest black nation in the world. The number of 
people with HBV infection in Nigeria is unknown. How-
ever, there have been numerous prevalence studies in 
various populations in Nigeria. Over 70% of the popula-
tion shows evidence of past infection with the virus and 
7.3–24% of the population has serological evidence of cur-
rent infection (average 13.7%). Thus, 19 million Nigerians 
are currently infected and approximately 5 million will 
die of causes related to HBV infection (10).
In Nigeria, HBV infection has been studied in several 
populations (11-21) (Table). Despite the availability of a safe 
and eﬀective vaccine since 1982 (22, 23) and its inclusion 
in Nigeria’s national immunization program in 1995, the 
vaccine only became available to the public in 2004 (24, 
25). Because of this late entry and absence of a national 
HBV surveillance program, the burden of hepatitis B re-
mains substantial. Most HBV infections in Nigeria occur 
by horizontal transmission (26, 27) as well as through 
blood transfusion (27, 28). A recent study showed that the 
median overall risk of becoming infected with HBV from 
a blood transfusion in sub-Saharan Africa was 4.3 per 1000 
units (29). This is a substantial number, as it translates to 
28,595 new HBV infections each year. A publication by the 
US Center for Disease Control(30) and a study in Nigeria 
(31) implicated injection from untrained community 
medical providers, body scariﬁcation, sharing of sharp 
body-piercing instruments, sharing of toothbrushes, 
and uvulectomy as reasons for the spread of HBV (16). A 
relatively high prevalence was demonstrated in a group 
of Nigerian female civil servants, a ﬁnding thought to be 
related to female circumcision. Studies from Northern 
Nigeria indicate that unprotected sex also plays a role in 
HBV transmission (21, 32).
HBV has evolved into at least 8 recognized genotypes, 
A–H (33-35). Extensive investigation of HBV genotypes in 
Nigeria (36, 37) showed that 95% of cases belong to geno-
type E. Analysis of HBV subspecies from 2 isolated rural 
communities in Nigeria revealed that individuals were 
infected with many diﬀerent HBV variants (38). Among 
the dominant HBV/E strain, variant sharing was exten-
sive, suggesting a very complex pattern of transmission. 
Numerous HBV strains may have been maintained with-
in the population through socio-cultural practices such 
as scariﬁcation marks, sharing of sharp instruments for 
body piercing, and the use of non-sterile medical and 
surgical instruments. These practices have also been as-
sociated with HIV transmission in Nigeria (39, 40).
It has been hypothesized that during the 1967–1969 
WHO smallpox and measles eradication program in 
West and Central Africa by arm-arm injections using jet 
injectors, signiﬁcant HBV transmission may have also oc-
curred (41-43). Such mass vaccination campaigns are as-
Population Studied Prevalence, %
Fakunle et al. (1977) (13) HCC a 49
Oli et al. (1980) (18) DM a 9.0 b
Abiodun et al. (1985) (11) Blood donors 10
Otu et al. (1987) (20) Liver cirrhosis, HCC 49
Bada et al. (1996) (12) Pregnant women 16
Olubuyide et al.(1997) (19)  HCC 59.3
Ndububa et al.(2001) (15) HCC 61
Sirisena et al. (2002) (21) Urban population 10.3
Mustapha et al. (2004) (19) HCC 64.7
Nwokediuko et al. (2011) (17) HCC 61.5
Nwokediuko et al. (2011) (16) Civil servants 7.6
Table. Prevalence of HBsAg in Various Nigerian Populations
a Abbreviations: DM, diabetes mellitus; HCC, hepatocellular carcinoma
b v.s 2.9 in control group788
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sociated with the dissemination of HBV/E in this region 
of Africa (41, 44). In addition, such massive introduction 
and the relatively recent expansion of HBV/E in Africa 
indicate a signiﬁcant shift in HBV/E epidemic dynamics 
in Africa over the past century (38). In the past decades, 
substantial improvement in the understanding of HBV 
biology, host immune responses, and natural disease 
course, combined with the recent availability of highly 
sensitive HBV DNA assays and the advent of eﬀective an-
tiviral drugs with diﬀerent mechanisms of action, have 
led to better therapeutic strategies for treating CHB in-
fection. Given the high endemicity of HBV infection, Af-
rican countries have the greatest opportunity to beneﬁt 
from these advancements. Unfortunately, these coun-
tries have not taken advantage of these opportunities. 
The objective of this review is to highlight the challenges 
in the management of CHB infection in Africa, using the 
situation in Nigeria as an example.
2. Lack of Accurate Statistics Regarding the 
Burden of HBV Infection 
CHB infection is largely asymptomatic; thus, accurate 
assessment of its prevalence is not possible unless all 
members of a population are screened. The HBV disease 
burden as outlined by the WHO is suﬃciently startling 
to prompt a public health response. Mortality estimates 
are conservative and based on cancer incidence from 
registries (45). In Africa, there are few high-quality regis-
tries; and the majority of them only record cases in cities, 
whereas hepatitis B prevalence is often highest in rural 
areas. The extent of the CHB situation in African coun-
tries was conveyed in the Global Policy on Viral Hepatitis 
published in 2010 by the World Hepatitis Alliance (WHA). 
This policy is the product of a study conducted by the 
WHA on behalf of the WHO across all 193 member states 
of the WHO. The study examined policies and programs 
aimed at preventing and controlling viral hepatitis and 
areas in which the WHO may be able to assist (46). As re-
vealed by the report, disease surveillance for hepatitis B 
is present in a total of 82% of countries in the world. This 
ranges from an average of less than 60% in Africa and 
South-East Asian regions to 90–100% in the Americas, 
Europe, and the Eastern Mediterranean (46). Sixty nine 
percent of the population of low-income countries live 
in areas that report no provisions for the surveillance 
of hepatitis B infection in any form. In Nigeria, there is 
practically no surveillance program in place for HBV in-
fection. In 71% of countries in Africa, no prevalence esti-
mates are available (46). Accurate data on the prevalence 
of hepatitis B are extremely diﬃcult to obtain in Nigeria 
and most African countries.  
3. Public Awareness and Education
Most patients with CHB have few or no symptoms; thus, 
these individuals remain undiagnosed. Detection of as-
ymptomatic individuals requires active screening pro-
grams. In low-prevalence areas of the world such as the 
USA, speciﬁc groups of individuals are considered to be 
at high risk of infection and are, therefore, recommend-
ed for screening. These include persons born in endemic 
areas, men who have sex with men, injecting drug users, 
dialysis patients, HIV-infected patients, pregnant wom-
en, families/households of infected persons, and individ-
uals who have sexual contacts with infected persons (47). 
For areas of high endemicity such as Nigeria, every indi-
vidual is at risk because he/she is born or lives in a highly 
endemic area. Awareness among the general population 
is quite low in Nigeria as well as in most countries in sub-
Saharan African. Of greater concern is the lack of proper 
education and awareness among health care providers, 
including doctors. This is because CHB is a disease that 
requires adequate explanation, counseling, and individ-
ualized assessment for successful anti-HBV therapy. The 
Society for Gastroenterology and Hepatology in Nigeria 
identiﬁed this lack of knowledge among health care pro-
viders and took a positive step towards addressing the 
situation by publishing the ﬁrst edition of a treatment 
guideline for Hepatitis B and C in Nigeria in 2009 (10). 
The circulation of this document needs to be widened 
so that doctors and other health workers will begin to 
implement the guideline provisions. Stigmatization 
is a formidable problem in the management of CHB in 
Africa. There is a signiﬁcant amount of ignorance in the 
populace regarding the causes, transmission, and clini-
cal course of HBV infection. Many people believe that 
there is no treatment for HBV infection. The stigma of 
being recognized as a HBV-infected person may provoke 
a feeling of shame in the community. In Nigeria, there 
have been cases of undergraduates being sent away from 
school by university authorities because they tested posi-
tive for hepatitis B surface antigen (HBsAg). This author 
has had reason to intervene in such cases by writing to 
the authorities of the universities and educating them 
on HBV infection, what causes it, how it is transmitted, 
the implications of a positive HBsAg test, and that an HB-
sAg-positive student does not constitute a health risk to 
fellow students. Transmission requires exchange of body 
ﬂuids or very close and intimate physical contact such 
as sexual intercourse. There have also been cases of job 
loss and other forms of discrimination against individu-
als with HBV infection. These rights abuses often occur 
in underdeveloped societies where the victims lack the 
capacity to seek redress; and even if they attempt to seek 
redress, the cost of justice are typically not within their 
reach. 
Another challenge for Nigerian patients is that they do 
not understand the phases of CHB infection and that not 
all phases require immediate treatment. Even after ex-
planation, many patients ﬁnd it diﬃcult to understand 
why an infection should not be treated as soon as it is 
detected without waiting for clear indications for treat-
ment. Physicians typically spend a signiﬁcant amount 
of time attempting to increase the patient’s understand-
ing regarding this point. Occasionally, patients suspect a 
lack of understanding of the disease by the doctor.789
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4. Personnel
The doctor-to-population ratio in Nigeria is 3 per 
10,000, compared to that of the USA which stands at 26 
per 10,000. There is an acute shortage of gastroenterolo-
gists, hepatologists, and anatomical pathologists in Ni-
geria. The country has a population of over 150 million, 
but has less than 40 hepatologists to care for patients 
with CHB (estimated to be approximately 19 million in 
Nigeria). One factor responsible for this situation is what 
is known as the “brain drain”. An estimated 13,272 physi-
cians trained in Sub-Saharan Africa are practicing in Aus-
tralia, Canada, the UK, and the USA (48). Approximately 
one-third of medical graduates from Nigerian medical 
schools migrate within 10 years of graduation to Canada, 
the UK, and the USA (49). The small number of gastro-
enterologists/hepatologists in Nigeria practice in large 
cities, while most patients with CHB live in rural areas. 
Liver biopsy is a critical procedure in the evaluation of 
patients with CHB. Information obtained from this ex-
amination is very useful in making decisions regarding 
treatment as well as determining prognosis. The number 
of doctors trained in this procedure, and more impor-
tantly, the number of specialists trained to interpret the 
ﬁndings is very low in Nigeria. Newer modalities of in-
vestigation that can be used to non-invasively diagnose 
liver ﬁbrosis are not yet available in most African coun-
tries, and where they are available, most physicians can 
only diﬀerentiate mild ﬁbrosis or no ﬁbrosis from severe 
ﬁbrosis (50).  
5. Referral System
An eﬀective referral system for patients does not exist 
in most African countries. In Nigeria, most people with 
CHB live in rural areas where facilities for performing 
simple tests for CHB are not available. Health facilities in 
rural areas are not capable of conducting the HBsAg test. 
Even when patients manage to undergo the test and are 
given a positive result, the attending health workers may 
not be adequately informed regarding the implications 
of a positive test and subsequent steps to follow. Some 
believe that there is no treatment for HBV infection. Most 
patients lack the ﬁnancial resources to attend larger 
hospitals located in cities for proper evaluation. Even 
when the ﬁnances are available, they may not appreciate 
the need for a more aggressive search for a solution be-
cause they are largely asymptomatic. This explains why 
most Nigerian patients with HBV infection present with 
decompensate cirrhosis, liver failure, and HCC. Studies 
have shown that if primary care specialists are provided 
with guidelines for referring CHB patients to specialists, 
the number of patients receiving specialist care increas-
es (51).
6. Lack of Diagnostic Facilities 
CHB is an expensive disease to manage. Evaluation of a 
patient involves collecting a thorough history, detailed 
physical examination, and laboratory tests. These tests 
include serological viral markers, biochemical tests to 
assess hepatic injury, hormone assays, hematological 
tests, imaging studies, molecular biological studies (HBV 
DNA viral load assessment), and liver biopsy. These tests 
must be performed during initial assessment and treat-
ment monitoring and at post-treatment follow-up. Many 
laboratories in Nigeria, including those in the teaching 
and specialist hospitals, can only conduct HBsAg screen-
ing. Other serological evaluations such as hepatitis B e 
antigen (HBeAg), hepatitis B e antibody (HBeAb), hepa-
titis B c antibody (HBcAb) (IgM, IgG), and hepatitis B s 
antibody (HBsAb) are often not conducted because of a 
lack of facilities and reagents. Currently, less than 6 cen-
ters in Nigeria are able to oﬀer HBV DNA viral load mea-
surements. Patients must travel hundreds of kilometers 
to such centers in order to undergo the test. The cost of 
these tests, particularly HBV DNA viral load assessment, 
is highly prohibitive. Few patients are able to complete 
all required tests for treatment initiation and monitor-
ing. Testing and vaccination for hepatitis A virus (HAV) 
is standard practice for all patients with CHB infection, 
because HAV infection is recognized as a cause of ﬂares in 
CHB. In most African countries, including Nigeria, there 
are typically no facilities for such testing and the vac-
cine is largely unavailable. Quality assurance in medical 
laboratories is a major issue in resource-poor countries. 
Prolonged power outages are frequent in Nigeria, which 
adversely aﬀects reagents stored in refrigerators. CHB 
patients in Africa are largely HBeAg-negative. Therefore, 
absence of HBeAg should not limit the treatment of Af-
rican patients. Most of what is known regarding HBV in 
Africans has been derived by extrapolation from studies 
done in Western countries and Asia. The exact duration 
of the immune tolerance phase in Africans is not clearly 
known. Treatment of HBeAg-negative CHB patients is 
more diﬃcult than treatment of HBeAg-positive CHB pa-
tients. Because of the high cost of virological tests, doc-
tors frequently resort to liver biopsies to make treatment 
decisions. 
7. Problems with Treatment
The most critical challenge in treating CHB is the high 
cost of medical care and antiviral drugs. The absence of 
an eﬀective health insurance program with adequate 
coverage in Nigeria further compounds the problem. Pa-
tients must pay out-of-pocket at the point of service deliv-
ery, and very few persons are able to aﬀord treatment. The 
result is that the majority of Nigerian patients diagnosed 
with CHB have not been properly evaluated and are not 
being treated. Pegylated interferon has a ﬁnite duration 
of treatment, and the patients do not become resistant. 
However, the cost of this treatment is not within the 
reach of most Nigerian patients. Monitoring which has 
to be instituted when a patient is on interferon therapy 
is another challenge. Frequent unpleasant side eﬀects 
are responsible for discontinuation of the therapy in 
some patients. Nucleoside/nucleotide analogues are not 790
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as expensive as pegylated interferon, but the end-point 
of treatment has not been determined. In Nigeria, there 
is indiscriminate use of lamivudine because of lack of ef-
fective control. Some patients place themselves on this 
drug without proper evaluation. Thus, resistance to lami-
vudine is likely to be very high. Other nucleoside/nucleo-
tide analogues (tenofovir, emtricitabine, and entecavir) 
are very expensive and largely unavailable in Nigeria.  
8. Co-Infections
8.1. HBV–HDV
The hepatitis D virus (HDV) is a defective virus with a cir-
cular RNA genome and a single structured protein, the 
hepatitis delta antigen. HBV has been shown to be impor-
tant for HDV assembly and propagation. The distribution 
of HDV infection in Africa is not clearly known. In Nige-
ria, despite the availability of robust literature regarding 
the prevalence of HBV, there is little published work on 
HDV. Few studies have been published on HDV in Nigeria 
(52-54), and much remains to be understood regarding 
its distribution. HDV testing is not routinely available in 
most health institutions, including teaching hospitals. 
Thus, it is not usually factored into the management of 
patients with CHB, particularly, if hepatitis is present in 
the face of little or no HBV DNA (low viral load) in HBsAg-
positive patients. Treatment of HDV infection requires 
interferon, which is expensive, requires close monitor-
ing, and causes many signiﬁcant side eﬀects. More read-
ily available and aﬀordable nucleoside/nucleotide ana-
logues are not used.
8.2. HBV–HCV
Infection with HBV and HCV may occur, as these two vi-
ruses share similar risk factors and transmission modes. 
As a consequence, co-infection with these two viruses oc-
curs frequently, particularly in geographic areas where 
both viruses are endemic. Problems encountered in 
managing co-infected patients are considerable because 
two viruses are involved and viral load monitoring dur-
ing treatment is necessary to determine which of them is 
dominant. This has obvious cost implications.
8.3. HBV–HIV
Since HBV and HIV share common routes of transmis-
sion, the prevalence of hepatitis B markers (HBsAg and 
HBcAb) in HIV-infected patients is remarkably high. 
Around the world, 90% of HIV-infected persons have 
biological signs of prior HBV infection (deﬁned by the 
presence of HBcAb) and 5–15% have a chronic infection 
(deﬁned by the presence of serum HBsAg) (55). In Africa, 
where HBV endemicity is high (> 8%), most HBV infections 
occur within the ﬁrst 5 years of life through close contact 
within households and medical or cultural procedures, 
e.g., scariﬁcation and tattoos (56). In these settings, the 
prevalence of HBV infection is often close to 15%, regard-
less of HIV-co-infection (57). In the era of broad-use of 
combined antiretroviral therapy (cART), the mortality 
and incidence of AIDS-deﬁning diseases have dramati-
cally declined (58). Liver diseases, particularly those asso-
ciated with HBV, have consequently emerged as a major 
cause of morbidity and mortality in HIV-infected persons 
(59-61). Persistent HBeAg reactivity and persistently high 
levels of HBV DNA have been associated with increased 
progression of hepatitis B in HIV-co-infected persons 
(60). Thus, therapeutic inhibition of HBV replication 
may be beneﬁcial, even if only for liver disease evolution. 
However, the restoration of innate and adaptive immu-
nity may be associated with ﬂares of necroinﬂammatory 
activity in the liver (62).
There have also been instances of triple infection with 
HIV, HBV, and HCV (59) and quadruple infection with HIV, 
HBV, HCV, and HDV (63). Similar combinations of infec-
tions may exist in resource-poor countries, but the neces-
sary laboratory support for diagnosing and monitoring 
such patients is typically lacking. The availability of nu-
cleoside/nucleotide analogues with dual activity against 
HIV and HBV has initiated a transition in the paradigm of 
HBV treatment in the context of HIV, along with many ad-
vantages and drawbacks. The use of drug combinations 
(emticitabine/tenofovir) and of dual activity drugs (te-
nofovir, lamivudine, and emtricitabine) help to simplify 
both HIV and HBV management, but the onset of resis-
tance warrants a strict viral follow-up. The incidence and 
spread of lamivudine-resistant and vaccine-escape HBV 
mutants is a major public health issue (57). 
HBV and HCV screening is included as part of the initial 
clinical and biological guidelines recommended by the 
WHO when initiating antiretroviral therapy (64), but is 
not often applied in resource-poor countries due to ﬁ-
nancial constraints. In HBsAg-negative patients, immu-
nization is strongly advised, but the late stages at which 
HIV infection is diagnosed and the cost of immunization 
which has to be borne by the patient limit eﬃcacy in 
resource-poor countries. When HIV-infected patients are 
diagnosed with CHB, a ﬁrst-line AIDS-associated retrovi-
rus (ARV) regime should include lamivudine and tenofo-
vir, as recommended by the WHO (65). In resource-poor 
countries, access to tenofovir remains problematic, and 
if contraindicated, other treatment options are typically 
unavailable. Broader and cheaper access to HBV screen-
ing and ﬁrst-line tenofovir-containing therapy should be 
advocated to prevent the emergence and spread of drug-
resistant strains (57, 66).
Transmission of HBV from mother-to-child (HBV-MTCT) 
is prevented by administration of hepatitis B immuno-
globulins (HBIgs). The high cost of HBIg makes its use 
in resource-poor settings a large problem. Furthermore, 
because HBV DNA levels are often very high during HBV-
HIV co-infection (67, 68), the use of HBIg may also fail. 
Lamivudine is useful in preventing HBV-MTCT (63), but 
better results are obtained when combined with HBIg; 
however, this in not practical in resource-poor settings. 
Concern has also been raised with regard to the increas-
ing prevalence of HCC following broader access to ARVs. 791
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Early diagnosis and treatment of HCC is unfortunately 
diﬃcult in resource-limited settings. Other challenges 
faced not only by resource-poor countries but indeed the 
entire global community in the management of HBV in-
fection include:
Genotype and mutations of the HBV genome (63, 67). 
This problem is exacerbated because in HIV-HBV co-infec-
tion, long exposure to nucleoside/nucleotide analogues 
that have been largely used to treat HIV enhances the op-
portunity for mutations to occur.
There is need for new viral markers in addition to HBV 
DNA. Treatment with potent drugs such as tenofovir 
leads to profound suppression of HBV DNA, but there is 
still a risk of developing cirrhosis and end-stage liver dis-
ease (ESLD). The covalently closed circular DNA (cccDNA) 
molecule is an interesting marker that may correlate 
better with treatment eﬃcacy (69, 70). In addition, the 
plasma HBsAg concentration has been shown to be an 
accurate predictor of HBsAg seroconversion and HBV 
clearance (71). In the context of HIV where nucleoside/
nucleotide analogues are more frequently used, HBsAg 
quantiﬁcation may help tailor HBV treatment more pre-
cisely and assist in early detection of non-responding 
patients whose anti-HBV treatment may consequently be 
more rapidly maximized.
9. Way Forward
Health Education/Awareness Campaigns should be di-
rected at the general populace and health care workers. 
For the general populace, it is important to understand 
HBV, how it is transmitted, its clinical course, and its com-
plications. Speciﬁc high-risk practices such as body scari-
ﬁcation, sharing of sharp instruments for body piercing, 
and unhealthy medical instrumentations should be 
discouraged. This is the best way to promote prevention 
measures. For health care workers, signiﬁcant training 
must be conducted to increase their knowledge base and 
correct erroneous ideas regarding hepatitis B. 
Thorough screening of blood and blood products prior 
to transfusion must be ensured in all health institutions.
Eﬀective referral systems for the care of HBV-infected pa-
tients should be established since most laboratory tests 
and treatments require experts.
Because of the large reservoir of asymptomatic infec-
tions in high prevalence areas, screening is the only way 
to identify these patients. People in these areas should 
take advantage of opportunities for screening whenever 
they visit a hospital for any reason. Other occasions when 
screening can be instituted include prior to blood or or-
gan donation, during school enrolment, military service, 
pre-employment, routine medical examination, and as 
part of medical insurance. Governments should make 
screening free and there should be an adequate manage-
ment plan for those who test positive and vaccination of 
those who test negative. Existing childhood immuniza-
tion programs should be intensiﬁed to improve cover-
age. The importance of this approach is illustrated by the 
experience in Taiwan (72). 
Guidelines for primary care physicians should be pub-
lished and existing ones should be updated to keep phy-
sicians informed on changes in CHB management. In re-
gions in which there have been substantial investments 
in services to deliver HIV treatment (courtesy of donor 
agencies), existing facilities and staﬀ could be expanded 
to incorporate HBV mono-infected individuals. As done 
in case of HIV/AIDS, eﬀorts can be devoted to negotiating 
aﬀordable drugs and establishing reliable supply chains. 
Pharmaceutical companies that produce anti-HBV drugs 
or HBV assays should lower the price of their products. 
Companies should provide support in the form of re-
search/educational grants and continuing medical edu-
cation programs for primary care physicians, internists, 
and gastroenterologists in capacity building. Technical 
and ﬁnancial assistance should be provided by wealthier 
nations of the world for screening, monitoring, and drug 
treatment of CHB. All recommendations of the Global 
Hepatitis Policy should be immediately implemented. 
Health insurances should be strengthened in scope and 
content, e.g., diseases such as CHB should be included.     
An adequate number of laboratories should be estab-
lished and located in such a way that patients will not 
have to travel long distances for laboratory tests. More 
hepatologists, pathologists, and allied staﬀ should be 
trained. Centers of excellence for Liver/Digestive diseases 
should be established. In such centers, resources can be 
pooled for eﬀective service delivery, research, and train-
ing. Such centers will aim at starting liver transplant pro-
grams in reasonable time. 
Acknowledgments
None declared.
Financial Disclosure 
None declared.
Funding/Support 
None declared.
References
1.    Lavanchy D. Hepatitis B virus epidemiology, disease burden, 
treatment, and current and emerging prevention and control 
measures. J Viral Hepat. 2004;11(2):97-107.
2.    Murray CJ, Lopez AD. Mortality by cause for eight regions 
of the world: Global Burden of Disease Study. Lancet. 
1997;349(9061):1269-76.
3.    Hepatitis B vaccines. Wkly Epidemiol Rec. 2004;79(28):255-63.
4.    Kramvis A, Kew MC. Epidemiology of hepatitis B virus in Africa, 
its genotypes and clinical associations of genotypes. Hepatol Res. 
2007;37(s1):S9-S19.
5.    Merican I, Guan R, Amarapuka D, Alexander MJ, Chutaputti A, 
Chien RN, et al. Chronic hepatitis B virus infection in Asian coun-
tries. J Gastroenterol Hepatol. 2000;15(12):1356-61.
6.    Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, Sim J. Pre-
immunization epidemiology of hepatitis B virus infection in 
South African children. J Med Virol. 1999;58(2):111-5.
7.    Beasley RP, Trepo C, Stevens CE, Szmuness W. The e antigen and 792
Hepat Mon. 2011;11(10):786-793
Chronic Hepatitis B Nwokediuko SC
vertical transmission of hepatitis B surface antigen. Am J Epide-
miol. 1977;105(2):94-8.
8.    Roingeard P, Diouf A, Sankale JL, Boye C, Mboup S, Diadhiou F, et 
al. Perinatal transmission of hepatitis B virus in Senegal, west 
Africa. Viral Immunol. 1993;6(1):65-73.
9.    The World Bank. World Development Indicators. Nigeria: Data 
and statistics.   [updated 2011 April 9]; Available from: http://
go.worldbank.org/HREMVJ8T90.
10  .  Idoko J, Meloni S, Muazu M, Nimzing L, Badung B, Hawkins C, et 
al. Impact of Hepatitis B Virus Infection on Human Immunode-
ﬁciency Virus Response to Antiretroviral Therapy in Nigeria. Clin 
Infect Dis. 2009;49(8):1268-73.
11  .  Abiodun PO, Ihongbe JC, Ubaru RJ. HBs antigen and blood do-
nors in Benin City, Nigeria. East Afr Med J. 1985;62(12):883-8.
12  .  Bada AS, Olatunji PO, Adewuyi JO, Iseniyi JO, Onile BA. Hepatitis 
B surface antigenaemia in Ilorin, Kwara State, Nigeria. Cent Afr J 
Med. 1996;42(5):139.
13  .  Fakunle YM, Ajdukiewicz AB, Greenwood BM, Edington GM. Pri-
mary liver cell carcinoma (PLCC) in the Northern Guinea Savan-
na of Nigeria. Trans R Soc Trop Med Hyg. 1977;71(4):335-7.
14  .  Mustapha SK, Pindiga UH. The Prevalence of Hepatitis B Virus in 
Patients With Hepatocellular Carcinoma in Gombe, North East-
ern Nigeria. Sahel Med J. 2004;6(4):104-6.
15  .  Ndububa DA, Ojo OS, Adeodu OO, Adetiloye VA, Olasode BJ, 
Famurewa OC, et al. Primary hepatocellular carcinoma in 
Ile-Ife, Nigeria: a prospective study of 154 cases. Niger J Med. 
2001;10(2):59-63.
16  .  Nwokediuko S, Ijoma UN. Relatively High Seroprevalence of 
Hepatitis B Surface Antigen in Female Civil Servants in Enugu 
State of Nigeria Sylvester Chuks Nwokediuko, Uchenna Ijoma. 
Euroasian J Hepato- Gastroenterol [Internet]. 2011; 1(1): Available 
from: http://www.jaypeejournals.com/eJournals/ShowText.aspx
?ID=1283&Type=Paid&TYP=TOP&IN=_eJournals/images/JPLOGO.
gif&IID=110&Value=20&isPDF=YES.
17  .  Nwokediuko S, Ijoma UN, Obienu O. Liver Cancer in Enugu, 
South East Nigeria. Insight. 2011;1(1):1-5.
18  .  Oli JM, Okafor GO. The prevalence of hepatitis B surface antigen 
in Nigerian diabetics. Trop Geogr Med. 1980;32(1):40-4.
19  .  Olubuyide IO, Aliyu B, Olalelye OA, Ola SO, Olawuyi F, Malabu 
UH, et al. Hepatitis B and C virus and hepatocellular carcinoma. 
Trans R Soc Trop Med Hyg. 1997;91(1):38-41.
  20.  Otu AA. Hepatocellular carcinoma, hepatic cirrhosis, and hepa-
titis B virus infection in Nigeria. Cancer. 1987;60(10):2581-5.
  21.  Sirisena ND, Njoku MO, Idoko JA, Isamade E, Barau C, Jelpe D, et 
al. Carriage rate of hepatitis-B surface antigen (HBsAg) in an ur-
ban community in Jos, Plateau State, Nigeria. Niger Postgrad Med 
J. 2002;9(1):7-10.
  22.  Beasley RP. Rocks along the road to the control of HBV and HCC. 
Ann Epidemiol. 2009;19(4):231-4.
  23.  Mast E, Mahoney F, Kane M, Margolis HS. Infectious Diseases Re-
lated To Travel. In: Plotkin SA, Orenstein WA, editors. Hepatitis B 
vaccine. Philadelphia: Saunders; 2004. p. 299-337.
  24.  Sadoh AE, Eregie CO. Age at presentation for infant immuniza-
tion in Nigeria: Implications for hepatitis B immunization. Pub-
lic health. 2008;122(12):1318-20.
 25.  World Health Organization. vaccine preventable diseases: moni-
toring system. 2006 global summary. Immunization Vaccines 
and Biologicals.   2005 [updated 2006 november]; Available 
from: http://www.who.int/vaccines-documents/GlobalSumma-
ry/GlobalSummary.pdf.
  26.  Amazigo UO, Chime AB. Hepatitis-B virus infection in rural and 
urban populations of eastern Nigeria: prevalence of serological 
markers. East Afr Med J. 1990;67(8):539-44.
  27.  Mutimer DJ, Olomu A, Skidmore S, Olomu N, Ratcliﬀe D, Rodg-
ers B, et al. Viral hepatitis in Nigeria--sickle-cell disease and com-
mercial blood donors. QJM. 1994;87(7):407-11.
  28.  Obiaya M, Ebohom PA. Blood Transfusion Hazards in Benin City, 
Nigeria. Nig Med J. 1982; 12:251-4.
 29.  Jayaraman S, Chalabi Z, Perel P, Guerriero C, Roberts I. The risk of 
transfusion-transmitted infections in sub-Saharan Africa. Trans-
fusion. 2010;50(2):433-42.
  30.  Centre for Disease control and prevention (CDC). Division of vi-
ral hepatitis B.   [updated 2009 May 25]; Available from: http://
www.cdc.gov/ncidod/diseases/none%20hepatitis/b/fact.
  31.  Nwokediuko S. Risk factors for Hepatitis B virus transmission 
in Nigerians: A case-control study. Internet J Gastroenterol [Inter-
net]. 2010; 10(1): Available from: http://www.ispub.com/journal/
the_internet_journal_of_gastroenterology/volume_10_num-
ber_1_14/article/risk-factors-for-hepatitis-b-virus-transmission-
in-nigerians-a-case-control-study.html.
  32.  Ivlustapha SK, Jibrin YB. The Prevalence of Hepatitis B Surface 
Antigenemia in Patients with Human Immunodeﬁciency Virus 
infection in Gombe, Nigeria. Ann Afrii Med. 2004;4:10-1.
  33.  Norder H, Hammas B, Lee SD, Bile K, Courouce AM, Mushahwar 
IK, et al. Genetic relatedness of hepatitis B viral strains of diverse 
geographical origin and natural variations in the primary struc-
ture of the surface antigen. J Gen Virol. 1993;74(Pt 7):1341-8.
  34.  Okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, 
Miyakawa Y, et al. Typing Hepatitis B Virus by Homology in Nu-
cleotide Sequence: Comparison of Surface Antigen Subtypes. J 
Gen Virol. 1988;69(10):2575-83.
  35.  Stuyver L, De Gendt S, Van Geyt C, Zoulim F, Fried M, Schinazi RF, 
et al. A new genotype of hepatitis B virus: complete genome and 
phylogenetic relatedness. J Gen Virol. 2000;81(Pt 1):67-74.
  36.  Mulders MN, Venard V, Njayou M, Edorh AP, Bola Oyefolu AO, Ke-
hinde M, et al. Low genetic diversity despite hyperendemicity of 
hepatitis B virus genotype E throughout West Africa. J Infect Dis. 
2004;190(2):400.
  37.  Olinger CM, Venard V, Njayou M, Oyefolu AO, Maiga I, Kemp AJ, 
et al. Phylogenetic analysis of the precore/core gene of hepatitis 
B virus genotypes E and A in West Africa: new subtypes, mixed 
infections and recombinations. J Gen Virol. 2006;87(Pt 5):1163-73.
  38.  Forbi JC, Vaughan G, Purdy MA, Campo DS, Xia GL, Ganova-Raeva 
LM, et al. Epidemic history and evolutionary dynamics of hepati-
tis B virus infection in two remote communities in rural Nigeria. 
PLoS One. 2010;5(7):e11615.
  39.  Isiugo-Abanihe UC. Sociocultural aspects of HIV/AIDS infection 
in Nigeria. Afr J Med Med Sci. 2006;35(Suppl):45-55.
  40.  Uwaezuoke SN, Nneli RO. Death of a G-6-P-D deﬁcient child with 
co-morbid HIV infection linked to scariﬁcation. J Trop Paediatr. 
2007;53:62-3.
  41.  Drucker E, Alcabes PG, Marx PA. The injection century: massive 
unsterile injections and the emergence of human pathogens. 
Lancet. 2001;358(9297):1989-92.
 42.  Foege WH, Eddins DL. Mass vaccination programs in developing 
countries. Prog Med Virol. 1973;15:205-43.
 43.  Foege WH, Millar JD, Henderson DA. Smallpox eradication in West 
and Central Africa. Bull World Health Organ. 1975;52(2):209-22.
 44.  Simonsen L, Kane A, Lloyd J, Zaﬀran M, Kane M. Unsafe injections 
in the developing world and transmission of bloodborne patho-
gens: a review. Bull World Health Organ. 1999;77(10):789-800.
  45.  Parkin DM, Sitas F, Chirenje M, Stein L, Abratt R, Wabinga H. 
Part I: Cancer in Indigenous Africans--burden, distribution, and 
trends. Lancet Oncol. 2008;9(7):683-92.
  46.  World Hepatitis Alliance. Viral Hepatitis: Global Policy.   [up-
dated 2011 April 10]; Available from: http://www.hivandhepatitis.
com/2010¬¬_conference/easl/docs/0420¬_2010_a.html.
47.   Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology. 
2001;34(6):1225.
48.    Mullan F. The metrics of the physician brain drain. N Engl J Med. 
2005;353(17):1810-8.
49.    Ihekweazu C, Anya I, Anosike E. Nigerian medical graduates: 
where are they now? Lancet. 2005;365(9474):1847-8.
50.    Castera L, Forns X, Alberti A. Non-invasive evaluation of liver ﬁ-
brosis using transient elastography. J Hepatol. 2008;48(5):835-47.
51.    Mostert MC, Richardus JH, de Man RA. Referral of chronic hepa-
titis B patients from primary to specialist care: making a simple 
guideline work. J Hepatol. 2004;41(6):1026-30.
52.   Nwokediuko SC, Ijeoma U. Seroprevalence of antibody to HDV in 
Nigerians with hepatitis B virus-related liver diseases. Niger J Clin 
Pract. 2009;12(4):439-42.
53.   Ojo OS, Akonai AK, Thursz M, Ndububa DA, Durosinmi MA, Adeo-
du OO, et al. Hepatitis D virus antigen in HBsAg positive chronic 
liver disease in Nigeria. East Afr Med J. 1998;75(6):329-31.
54.    Ojo OS, Thursz M, Thomas HC, Ndububa DA, Adeodu OO, Rotimi 
O, et al. Hepatitis B virus markers, hepatitis D virus antigen and 
hepatitis C virus antibodies in Nigerian patients with chronic 
liver disease. East Afr Med J. 1995;72(11):719-21.793
Hepat Mon. 2011;11(10):786-793
Chronic Hepatitis B Nwokediuko SC
55.    Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J 
Hepatol. 2006;44(1 Suppl):S6-9.
56.    Adewole OO, Anteyi E, Ajuwon Z, Wada I, Elegba F, Ahmed P, et 
al. Hepatitis B and C virus co-infection in Nigerian patients with 
HIV infection. J Infect Dev Ctries. 2009;3(5):369-75.
57.    Hoﬀmann CJ, Thio CL. Clinical implications of HIV and hepatitis 
B co-infection in Asia and Africa. Lancet Infect Dis. 2007;7(6):402-9.
58.   Palella FJ, Jr., Baker RK, Moorman AC, Chmiel JS, Wood KC, Brooks 
JT, et al. Mortality in the highly active antiretroviral therapy era: 
changing causes of death and disease in the HIV outpatient 
study. J Acquir Immune Deﬁc Syndr. 2006;43(1):27-34.
59.   Konopnicki D, Mocroft A, de Wit S, Antunes F, Ledergerber B, Katla-
ma C, et al. Hepatitis B and HIV: prevalence, AIDS progression, 
response to highly active antiretroviral therapy and increased 
mortality in the EuroSIDA cohort. Aids. 2005;19(6):593-601.
60.    Lewden C, May T, Rosenthal E, Burty C, Bonnet F, Costagliola D, 
et al. Changes in causes of death among adults infected by HIV 
between 2000 and 2005: The” Mortalite 2000 and 2005” surveys 
(ANRS EN19 and Mortavic). J Acquir Immune Deﬁc. 2008;48(5):590.
61.    Mocroft A, Brettle R, Kirk O, Blaxhult A, Parkin JM, Antunes F, 
et al. Changes in the cause of death among HIV positive sub-
jects across Europe: results from the EuroSIDA study. Aids. 
2002;16(12):1663.
62.    Puoti M, Torti C, Bruno R, Filice G, Carosi G. Natural history of 
chronic hepatitis B in co-infected patients. J hepatol. 2006;44(1 
Suppl):S65-S70.
63.    Lacombe K, Massari V, Girard PM, Serfaty L, Gozlan J, Pialoux G, 
et al. Major role of hepatitis B genotypes in liver ﬁbrosis during 
coinfection with HIV. Aids. 2006;20(3):419-27.
64.   World Health Organization. Essential prevention and care 
interventions for adults and adolescents living with HIV in re-
source-limited settings. Switzerland: WHO. 2008 [updated 2009 
October 12]; Available from: http://www.who.int/hiv/pub/plhiv/
plhiv_treatment_care.pdf.
65.    World Health Organization. Priority Interventions. HIV/AIDS 
prevention and care in the health sector.   [updated 2009 Octo-
ber 12]; Available from: http://www.who.int/entity/hiv/pub/prior-
ity_interventions_web.pdf.
66.    Lessells RJ, Main J, Cooke GS. HIV and hepatitis B co-infection in 
Africa. Lancet Infect Dis. 2008;8(4):210-1.
67.    Liu SL, Dong Y, Zhang L, Li MW, Wo JE, Lu LW, et al. Inﬂuence of 
HBV gene heterogeneity on the failure of immunization with 
HBV vaccines in eastern China. Arch Virol. 2009;154(3):437-43.
68.    Wiseman E, Fraser MA, Holden S, Glass A, Kidson BL, Heron LG, 
et al. Perinatal transmission of hepatitis B virus: an Australian 
experience. Med J Aust. 2009;190(9):489-92.
69.    Chan HLY, Tse CH, Mo F, Koh J, Wong VWS, Wong GLH, et al. High 
viral load and hepatitis B virus subgenotype ce are associated 
with increased risk of hepatocellular carcinoma. J clin oncol. 
2008;26(2):177.
70.    Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Peters-
en J, Lau G, et al. Persistence of cccDNA during the natural his-
tory of chronic hepatitis B and decline during adefovir dipivoxil 
therapy. Gastroenterology. 2004;126(7):1750-8.
71.    Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin 
C, et al. Hepatitis B virus surface antigen levels: a guide to sus-
tained response to peginterferon alfa-2a in HBeAg-negative 
chronic hepatitis B. Hepatology. 2009;49(4):1141-50.
72.    Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. 
Universal hepatitis B vaccination in Taiwan and the incidence 
of hepatocellular carcinoma in children. New Engl J Med. 
1997;336(26):1855-9.